Related Articles
Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report
Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells
Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma‑associated mRNAs in high‑risk neuroblastoma patients
Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients
MYCN amplicon junctions as tumor-specific targets for minimal residual disease detection in neuroblastoma